Compare Five9 Inc (FIVN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Five9 Inc trades at $31.46 (market cap $2.44B), while Vertex Pharmaceuticals Incorporated trades at $527.99 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 55× Five9 Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Five9 Inc nearer its low. Which is the better fit depends on your goals.
| FIVN | VRTX | |
|---|---|---|
Market Cap | $2.44B | $134.25B |
Sector | Technology | Health |
52-Week High | $34.48 | $529.65 |
52-Week Low | $13.61 | $376.62 |
Enterprise Value | $2.59B | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $34.48, up 1.44% today and near its 52-week high of $34.58. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Revenue growth accelerated to 10% in Q2 2026, driven by AI-powered subscription services, while profitability improved with net income turning positive in 2025 after years of losses.
Outlook remains positive with 61% analyst buy ratings and a consensus price target of $32.67, though current price exceeds this target. Key risks include high valuation multiples (P/E 48), ongoing legal scrutiny regarding fiduciary duties, and competitive pressures in the CX software space. The company's leadership refresh and AI integration provide growth catalysts.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
